CD22(low)/Bcl-2(high) expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia

[Figure: see text]

Detalles Bibliográficos
Autores principales: Wintering, Astrid, Ishiyama, Kenichi, Tamaki, Stanley, Tamaki, Courtney, Fandel, Joshua, Ji, Lingyun, Wood, Brent L., Shah, Nirali N., Yuan, Constance M., O’Brien, Maureen M., Loh, Mignon L., Diaz-Flores, Ernesto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840233/
https://www.ncbi.nlm.nih.gov/pubmed/35500285
http://dx.doi.org/10.1182/bloodadvances.2021006810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840233/
https://www.ncbi.nlm.nih.gov/pubmed/35500285
http://dx.doi.org/10.1182/bloodadvances.2021006810

Ejemplares similares